EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study

Robert Pirker, Jose R. Pereira, Joachim Von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo De Marinis, Wilfried E E Eberhardt, Luis Paz-Ares, Stephan Störkel, Karl Maria Schumacher, Anja Von Heydebreck, Ilhan Celik, Kenneth J. O'Byrne

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·762-0·996; p=0·044) in patients with advanced non-small-cell lung cancer (NSCLC). To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients. Methods: We used prospectively collected tumour EGFR expression data to generate an immunohistochemistry score for FLEX study patients on a continuous scale of 0-300. We used response data to select an outcome-based discriminatory threshold immunohistochemistry score for EGFR expression of 200. Treatment outcome was analysed in patients with low (immunohistochemistry score

Original languageEnglish
Pages (from-to)33-42
Number of pages10
JournalThe Lancet Oncology
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2012

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study'. Together they form a unique fingerprint.

Cite this